{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"106","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"-Time to platelet engraftment is measured by determining the first of 3 consecutive measurements of platelet count ≥ 20,000/ul without platelet transfusion support for 7 days.","dispersionType":"Full Range","groups":[{"description":"Conditioning Regimens\n\n* fludarabine and busulfan +/- thymoglobulin\n* fractionated total body irradiation and cyclophosphamide\n* busulfan and cyclophosphamide\n* single dose total body irradiation and cyclophosphamide\n\nDay -2 = GvHD prophylaxis\n\nDay 0 or +1 = PBSC transplant\n\nDay +7 until neutrophil engraftment = G-CSF 5 ug/kg/day","id":"OG000","title":"Arm 2 - Recipient"}],"paramType":"MEDIAN","populationDescription":"1 recipient did not have platelet engraftment by Day 180 and is not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to Day 180","title":"Kinetics of Immune Reconstitution as Measured by Time to Platelet Engraftment (Recipient Only)","type":"SECONDARY","unitOfMeasure":"days"}